Share𝕏inWA

Isomorphic Labs Raises $5B to Bring AI Drugs to Trials

TechorCoffee
TechorCoffee
Contributing Writer

Published (Updated )

Isomorphic Labs Raises $5B to Bring AI Drugs to Trials

Quick answer

The announcement

Isomorphic Labs announced the $5 billion Series C on November 17, 2026, in London, through a press release carried by PR Newswire. The company is based in London and was spun out of Google DeepMind in 2021 to apply the AI behind AlphaFold to the problem of designing new medicines.

Researchers in white coats working at lab benches in a bright modern biotech laboratory in London

The size of the round is what made the announcement travel so fast. A $5 billion single venture round is enormous by any standard, and in biotech it is without precedent. BioSpace, the life-sciences news outlet, called it the largest venture round in biotech history, and the claim has been repeated across coverage of the deal in the days since. The round was co-led by Greenoaks and Sequoia Capital, two firms with long track records in technology investing. Andreessen Horowitz joined as a new investor. Alphabet, Google's parent company, made what Isomorphic describes as continued significant investment. All of the company's existing investors took part, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. That last detail matters. When every existing investor returns for a round of this size, it signals that the people who already know the company best are willing to put in far more money. The company also described the round as oversubscribed, meaning that demand from investors was greater than the amount it was looking to raise.

The funding in numbers

The Series C is the third large external round Isomorphic has closed in under 20 months, and the amounts have grown sharply each time.

A record round for biotech

Calling the Series C the largest venture round in biotech history is a big claim, and it is worth asking what it rests on. BioSpace made the call in its coverage of the announcement, and the figure itself is not in dispute: $5 billion in a single venture round for a drug-discovery company has no obvious precedent. The record matters for two reasons. First, it shows how much capital is now flowing into AI drug discovery specifically, rather than into biotech in general. Investors are treating AI-designed medicines as a distinct category, one that deserves funding at a scale normally reserved for the biggest technology companies. Second, it raises the stakes for Isomorphic itself. A company that has raised $7.7 billion in under 20 months will be expected to show results to match. The money buys time and talent, but it also creates pressure to turn the platform into medicines that reach human trials, and eventually into medicines that reach patients.

What IsoDDE actually does

At the centre of Isomorphic's pitch is IsoDDE, its drug-design engine, which the company unveiled on February 10, 2026, with benchmarks published in a company technical report. The idea behind the engine is straightforward to describe, even if the engineering is not. Traditional drug discovery starts with a disease target, usually a protein, and then searches through vast libraries of chemical compounds to find one that might bind to it and change its behaviour. The process is slow, expensive and mostly fails: the great majority of candidate compounds never become medicines. Isomorphic's approach is to design the drug with AI instead of searching for it. The engine is built to do the following:

Computer monitor showing a colourful AI-designed drug molecule and protein structure in a research lab

The company says its programs are focused on oncology and immunology, two areas where new medicines are badly needed and where the biology is complex enough that a better design tool could make a real difference. It has also reported positive preclinical results from its own programs. That last phrase needs careful handling. Preclinical means work done in computers and in laboratory experiments, not in people. A positive preclinical result is a genuine milestone, but it is an early one. Most drug candidates that look promising in preclinical work still fail when they reach human trials, and that is true whether they were designed by AI or by traditional methods.

Where the $5 billion goes

The announcement sets out broad areas where the money will be spent, but it gives no dollar split between them and no schedule of milestones. The areas named are:

The man behind it: Demis Hassabis

Isomorphic's founder and chief executive is Demis Hassabis, who won the 2024 Nobel Prize in Chemistry for his work on AlphaFold, the AI system that predicts protein structures. AlphaFold solved a problem that had challenged biologists for decades, and it is the foundation on which Isomorphic is built. Hassabis recently left his role as head of DeepMind to focus on Isomorphic, moving to a chairman role at DeepMind. The move is a signal in itself: the person who led one of the world's most important AI labs has chosen to spend his time on drug discovery instead. His public statements about timing have shifted over time, and the shift is worth recording honestly. He previously said he wanted Isomorphic's first drugs in clinical trials by the end of 2025, then later spoke of the end of 2026. In a Bloomberg interview published on November 17, 2026, the same day as the funding announcement, he declined to give a new date. That refusal is not a failure, but it is informative. It suggests the company is not willing to commit publicly to a trial date it may not meet, and it means that anyone looking for a firm timeline will not find one in the announcement.

Big pharma is already on board

One of the strongest signals in the announcement is the list of pharmaceutical partners named by the company: Novartis, Eli Lilly and Johnson & Johnson. These are three of the largest drug makers in the world, and their involvement gives Isomorphic's platform a credibility that funding alone cannot buy. Partnerships with large drug companies work in both directions. For Isomorphic, they bring money, expertise in running trials, and a route to market for any medicine that succeeds. For the drug companies, they bring access to an AI design engine they would struggle to build themselves. The partnerships also matter because they show that the industry's biggest players are taking AI drug design seriously as a practical tool, not just as a research curiosity. Novartis, Eli Lilly and Johnson & Johnson do not lend their names to speculative projects lightly, and their presence in the announcement is a vote of confidence in the platform. What the announcement does not say is how much each partner is contributing, or what specific programs they are working on together. Those details are usually kept private, and they are not part of this announcement.

Why Alphabet's stake matters

Alphabet, Google's parent company, is not just an investor in Isomorphic. According to UK Companies House records, Alphabet owns 75% or more of Isomorphic's shares and voting rights. That level of ownership makes Isomorphic something unusual: a company that raises venture rounds like an independent startup, but that is majority-owned by one of the world's largest technology companies. The arrangement gives Isomorphic access to Alphabet's computing power, research and talent, and it gives Alphabet a major position in AI drug discovery. It also raises questions that investors and observers will keep asking. How independent is Isomorphic's decision-making when one shareholder controls three quarters of the votes? None of those questions has a public answer in the announcement, and they may never have one. But the ownership structure is a fact worth knowing, because it shapes how the company is governed and how its future is decided.

What this does not mean yet

A $5 billion funding round is a huge event, but it is important to be clear about what it does not mean.

The $50 billion question

One figure has been widely discussed alongside the funding, and it needs to be labelled carefully. Bloomberg reported earlier in November 2026 that Isomorphic was seeking funding at a valuation of about $50 billion. That figure is reported, not confirmed. The company has not disclosed its valuation, and the funding announcement says nothing about it. A reported valuation from a news outlet, even a well-sourced one, is not the same as a confirmed figure from the company or its investors. If the reported figure were accurate, it would place Isomorphic among the most valuable private biotech companies in the world, and it would mean the $5 billion round bought investors roughly a tenth of the company. But without confirmation, that arithmetic is speculation, and it should be treated as such. The reason the valuation question matters is that it shapes expectations. A company valued at $50 billion is expected to produce medicines worth far more than that over time. A company valued at a lower figure faces lower expectations. Until Isomorphic or its investors confirm a number, the honest position is to say that the valuation was not disclosed, and that $50 billion is a reported figure only.

What to watch next

The funding announcement is the start of the story, not the end of it. The developments worth watching over the coming months are:

The bottom line

Isomorphic Labs has raised $5 billion in a Series C round, co-led by Greenoaks and Sequoia Capital, taking its total external funding to about $7.7 billion in under 20 months. The round has been called the largest venture round in biotech history, and it gives the company the resources to develop its IsoDDE drug-design engine, build new biology models and prepare for clinical trials. But no drug candidate has been named, no trial date has been set, and the valuation was not disclosed. The funding is a remarkable vote of confidence in AI drug discovery. The proof will come when a drug designed by the platform enters a human trial.

FAQs

What is Isomorphic Labs?

Isomorphic Labs is an AI drug-discovery company spun out of Google DeepMind in 2021. It uses AI to design new medicines, starting with its IsoDDE drug-design engine, and its programs focus on oncology and immunology.

How much did Isomorphic Labs raise in its Series C?

The company raised $5 billion in a Series C round announced on November 17, 2026, co-led by Greenoaks and Sequoia Capital. Its total external funding now stands at about $7.7 billion across three rounds in under 20 months.

Is this the largest biotech funding round ever?

BioSpace called the $5 billion Series C the largest venture round in biotech history. The size of the round is not in dispute, and no larger biotech venture round has been reported.

What is IsoDDE?

IsoDDE is Isomorphic Labs' drug-design engine, unveiled on February 10, 2026. It is designed to create new drug molecules with AI, predicting how they bind to target proteins and refining them for the properties a real medicine needs.

When will Isomorphic's first drug enter clinical trials?

No date has been given. CEO Demis Hassabis previously targeted the end of 2026, after earlier aiming for the end of 2025, and in a Bloomberg interview published on November 17, 2026, he declined to give a new date.

What is Isomorphic Labs valued at?

The company has not disclosed its valuation. Bloomberg reported earlier in November 2026 that it was seeking funding at about a $50 billion valuation, but that figure is reported and unconfirmed.

Who are Isomorphic Labs' pharmaceutical partners?

The company names Novartis, Eli Lilly and Johnson & Johnson as external pharmaceutical partners. Alphabet, its majority owner, is also a significant investor in the round.

Who owns Isomorphic Labs?

Alphabet owns 75% or more of Isomorphic's shares and voting rights, according to UK Companies House records. The company was spun out of Google DeepMind in 2021 and is led by founder and CEO Demis Hassabis.

Was this article helpful?

TechorCoffee

Written By

TechorCoffee

Contributing Writer

TechorCoffee is a technology reporter and software creator writing reviews and tutorials for TechOrCoffee.

Comments (0)

Sort by:

Leave a Comment

Loading comments...

Read Next